The safety record in plain numbers

Safety is the question any hip patient asks first. Across more than 19,000 ChondroFiller® treatments performed globally since 2013, zero serious adverse device effects (SADEs) have been recorded — a SADE being any event causing organ damage, hospitalisation, or lasting injury directly attributable to the device. That figure originates from Meidrix Biomedicals GmbH's Clinical Evaluation Report (CER Version 09, April 2025), the mandatory regulatory submission for a CE-marked Class III implant.

The overall device complaint rate sits at approximately 0.06% — roughly one in every 1,500 procedures. The most frequently logged issue is non-gelation, where the liquid collagen fails to set properly inside the defect, affecting around 0.01% of cases. Non-gelation is a procedural outcome; it does not cause patient harm. A 2025 prospective study by Matta et al. independently found no significant difference in complications between ChondroFiller-treated patients and matched controls, adding external corroboration beyond the manufacturer's own regulatory data.

The 19,000-case series spans eight joint types — knee, hip, shoulder, ankle, wrist, elbow, foot, and hand — making it the largest real-world safety dataset for any injectable collagen cartilage scaffold. Hip joint treatments are included within that pool.

The entire dataset is observational and manufacturer-sponsored; no blinded randomised controlled trial has been published. That is a factual characteristic of the evidence base — one the CER itself acknowledges — and it sits alongside a safety signal that is, within those design constraints, consistent and of substantial scale.

Why patient selection is part of the safety story

Behind that headline figure sits a deliberate eligibility process — and the two cannot be separated. The zero serious adverse event rate reflects outcomes in a specific, carefully defined patient population. Applying it more broadly would misread what the evidence actually shows.

ChondroFiller injection is indicated for focal Grade III/IV cartilage defects up to 6 cm² in the hip joint, where the damaged area is clearly bounded by healthy surrounding cartilage. Grade III/IV in the hip means the cartilage has worn through significantly — down to exposed bone in places — but the joint itself remains structurally intact. That distinction matters: diffuse or end-stage hip osteoarthritis, where the cartilage loss is widespread across the joint rather than focal, sits outside the indication. At that stage, a different conversation about joint replacement or other pathways is the appropriate one.

On contraindications: the one absolute exclusion is a known sensitivity to murine (mouse-derived) Type I collagen, the material from which the scaffold is made. This is rare, and routine screening identifies it before any injection is planned. Relative contraindications — active joint infection, bleeding disorders, active malignancy, and pregnancy — follow standard intra-articular precautions.

Eligibility screening is not an obstacle to treatment; it is precisely why the safety record holds. The scaffold has not been studied outside its indicated population at this scale, so the 0% SADE figure is meaningful only for patients who meet the criteria.

At Lincolnshire Hip, suitability for ChondroFiller injection is confirmed through clinical assessment and imaging before any treatment is planned.

How the injection works inside the hip joint

The ChondroFiller injection itself is straightforward in principle, even if the biology underneath it is not. The product is a liquid solution of murine-derived Type I collagen — acellular, meaning it contains no living cells, neither harvested from a donor nor taken from the patient. Once injected, it responds to body temperature and the joint environment by polymerising into a stable gel within minutes, filling the contours of the cartilage defect and holding position against the surrounding tissue.

The hip joint is a ball-and-socket joint: the rounded femoral head sits within the cup-shaped acetabulum, both surfaces lined with hyaline cartilage. Focal chondral lesions in the hip occur most frequently at the anterosuperior acetabulum or the femoral head — the areas that bear the greatest load and shear. It is into these defect sites that the collagen scaffold is placed.

Once the gel is in position, it acts as a matrix for matrix-induced chondrogenesis: progenitor cells from the surrounding tissue migrate into the scaffold, mature into chondrocyte-like cells, and begin laying down new cartilage repair tissue. The scaffold then gradually resorbs as the repair tissue matures. The product provides the architecture; the body provides the cells.

Delivery is by outpatient ultrasound-guided injection — or fluoroscopic guidance where preferred — under local anaesthesia. No operating theatre, no general anaesthesia, and no hospital admission are required.

What happens after the injection

In the first day or two after a ChondroFiller injection, most patients notice localised swelling around the hip, a dull pressure-like ache, and some joint stiffness. These effects typically peak at around 24 hours and settle without specific intervention by 48 to 72 hours. They are a physiological response to the collagen scaffold being placed inside the joint — not a sign that something has gone wrong — and patients who know to expect them are far less likely to misinterpret a normal recovery window as a complication.

Because no general anaesthesia is involved, there is no theatre recovery period; patients leave the clinic on the same day.

Meaningful functional improvement builds over months rather than days. As the scaffold integrates and the biological repair process progresses, symptom change tends to arrive in gradual steps rather than a single obvious shift. Published outcome studies report MOCART imaging scores of 81.6 to 84.3 — indicating more than 80% defect fill and good tissue integration with surrounding cartilage — alongside functional score improvements (IKDC and modified Harris Hip Score) of approximately 30 points sustained at three years, comfortably above the threshold for clinically meaningful change. These figures derive from multi-joint datasets that include hip cases but do not report hip outcomes in isolation; individual results will vary accordingly.

ChondroFiller versus other hip cartilage options

Understanding the hip joint treatment landscape helps patients ask better questions before their consultation. Three broad categories apply for focal chondral lesions.

Microfracture — historically the default first-line for small defects — works by penetrating the subchondral bone plate to draw marrow cells into the lesion. The repair tissue produced is fibrocartilage rather than hyaline-like cartilage: mechanically inferior, and in published series it degrades at two to three years. Repeated marrow stimulation also damages the subchondral bone plate itself, potentially narrowing the options available if further treatment becomes necessary.

ACI and MACI involve two separate procedures — a cartilage biopsy at the first operation, a period of cell culture, then re-implantation under general anaesthesia. They remain clinically valid, particularly for larger defects, but the resource requirement and recovery period are substantially greater than an outpatient injection pathway.

The ChondroFiller injection sits in a distinct category: image-guided, single-stage, and clinic-based. For hip patients in Lincolnshire who may face lengthy referral waits or considerable travel to access surgical alternatives, that practical difference can carry real weight. It is one reason Lincolnshire Hip includes ChondroFiller injection in its pathway for suitable candidates.

The clinical urgency underlying all three options is the same: focal chondral lesions at the anterosuperior acetabulum and femoral head consistently predict progression to total hip replacement when left untreated. The safety evidence for ChondroFiller injection discussed in the opening sections is drawn from observational post-market data across more than 19,000 treatments — a substantial real-world dataset, though not a controlled head-to-head trial, as noted earlier.

Getting assessed for ChondroFiller at Lincolnshire Hip

Patients across Lincolnshire and the wider East Midlands can be seen at Lincolnshire Hip without a GP referral — clinics run in Sleaford and Grantham, keeping access local for patients who would otherwise face significant travel to reach specialist hip services.

Assessment begins with a clinical evaluation and imaging review to establish whether a focal hip cartilage defect falls within the ChondroFiller injection indication: defect size, lesion grade, condition of the surrounding cartilage, and absence of contraindications. That eligibility process is not a formality — as the earlier sections explain, it is the mechanism by which the zero serious adverse event record is maintained. Patients who do not meet the criteria will be advised on appropriate alternatives within the hip pathway; the assessment is a starting conversation, not a commitment to a specific treatment.

For patients weighing the safety profile discussed throughout this article, the practical next step is that assessment — not a referral, not a waiting list. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] Editorial Commentary: Hip Chondral Defect Treatment Requires Cells, Signal, and Scaffold. (2022). https://doi.org/10.1016/j.arthro.2022.06.007 https://doi.org/10.1016/j.arthro.2022.06.007